title: TFIIB-related factor 2 over expression is a prognosis marker for early-stage non-small cell lung cancer correlated with tumor angiogenesis.
abstract: BACKGROUND
  The aim of this study was to examine BRF2 expression in patients with non-small cell lung cancer (NSCLC) and explore the relationship of BRF2 protein with clinicopathologic factors, tumor angiogenesis and prognosis.
  
  
  METHODS
  Both BRF2 protein and intratumoral microvessels were examined by immunohistochemical staining in 107 non-small cell lung cancer patients. Intratumoral microvessel density (MVD) was measured by counting CD-34 positive immunostained endothelial cells. Western blot and RT-PCR analyses were utilized to investigate the BRF2 expression status in tissues.
  
  
  RESULTS
  A notably higher level of BRF2 expression was found in NSCLC tissues at protein levels. In addition, univariate and multivariate analysis demonstrated that BRF2 protein over-expression and high MVD were significantly associated with tumor relapse. Although BRF2 overexpression and high MVD indicated poor 5-year overall survival (p = 0.004 and p = 0.019, respectively), multivariate analysis demonstrated that only BRF2 overexpression was an independent prognostic factor for unfavorable overall survival (P = 0.021).
  
  
  CONCLUSIONS
  BRF2 is a promising biomarker to identify individuals with poor prognostic potential and a possible target for anti-angiogenic therapy for patients with early-stage NSCLC.
authors: Department of Thoracic Surgery, Qilu Hospital, Shandong University, Jinan, P. R. China.
authors: Ming
authors: M
authors: Lu
authors: Department of Thoracic Surgery, Qilu Hospital, Shandong University, Jinan, P. R. China.
authors: Hui
authors: H
authors: Tian
authors: Department of Thoracic Surgery, Qilu Hospital, Shandong University, Jinan, P. R. China.
authors: Weiming
authors: W
authors: Yue
authors: Department of Thoracic Surgery, Qilu Hospital, Shandong University, Jinan, P. R. China.
authors: Lin
authors: L
authors: Li
authors: Department of Thoracic Surgery, Qilu Hospital, Shandong University, Jinan, P. R. China.
authors: Shuhai
authors: S
authors: Li
authors: Department of Thoracic Surgery, Qilu Hospital, Shandong University, Jinan, P. R. China.
authors: Lei
authors: L
authors: Qi
authors: Department of Thoracic Surgery, Qilu Hospital, Shandong University, Jinan, P. R. China.
authors: Wensi
authors: W
authors: Hu
authors: Department of Thoracic Surgery, Qilu Hospital, Shandong University, Jinan, P. R. China.
authors: Cun
authors: C
authors: Gao
authors: Department of Thoracic Surgery, Qilu Hospital, Shandong University, Jinan, P. R. China.
authors: Libo
authors: L
authors: Si
mesh_terms: D000368:Aged; D018952:Antigens, CD34 / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000378:metabolism; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000378:metabolism / Q000401:mortality; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000401:mortality; D008297:Male; D008833:Microcirculation; D008875:Middle Aged; D015999:Multivariate Analysis; D009389:Neovascularization, Pathologic; D011379:Prognosis; D012008:Recurrence; D035361:Transcription Factor TFIIIB / Q000235:genetics* / Q000378:metabolism*; D016896:Treatment Outcome
chemical_list: D018952:Antigens, CD34; C416185:BRF2 protein, human; D014408:Biomarkers, Tumor; D035361:Transcription Factor TFIIIB